Latest Camber Capital Management LP Stock Portfolio
Camber Capital Management LP Performance:
2025 Q1: 0.05%YTD: 0.05%2024: 0.55%
Performance for 2025 Q1 is 0.05%, and YTD is 0.05%, and 2024 is 0.55%.
About Camber Capital Management LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Camber Capital Management LP reported an equity portfolio of $2.8 Billions as of 31 Mar, 2025.
The top stock holdings of Camber Capital Management LP are ZBH, BAX, HUM. The fund has invested 9.1% of it's portfolio in ZIMMER BIOMET HOLDINGS INC and 7% of portfolio in BAXTER INTL INC.
The fund managers got completely rid off MEDTRONIC PLC (MDT), JAZZ PHARMACEUTICALS PLC (JAZZ) and QIAGEN NV stocks. They significantly reduced their stock positions in ORASURE TECHNOLOGIES INC (OSUR), ASCENDIS PHARMA A/S and BROOKDALE SR LIVING INC (BKD). Camber Capital Management LP opened new stock positions in QIAGEN NV. The fund showed a lot of confidence in some stocks as they added substantially to ZIMMER BIOMET HOLDINGS INC (ZBH), THE CIGNA GROUP (CI) and BAXTER INTL INC (BAX).
The top stock holdings of Camber Capital Management LP are ZBH, BAX, HUM. The fund has invested 9.1% of it's portfolio in ZIMMER BIOMET HOLDINGS INC and 7% of portfolio in BAXTER INTL INC.
The fund managers got completely rid off MEDTRONIC PLC (MDT), JAZZ PHARMACEUTICALS PLC (JAZZ) and QIAGEN NV stocks. They significantly reduced their stock positions in ORASURE TECHNOLOGIES INC (OSUR), ASCENDIS PHARMA A/S and BROOKDALE SR LIVING INC (BKD). Camber Capital Management LP opened new stock positions in QIAGEN NV. The fund showed a lot of confidence in some stocks as they added substantially to ZIMMER BIOMET HOLDINGS INC (ZBH), THE CIGNA GROUP (CI) and BAXTER INTL INC (BAX).
Camber Capital Management LP Annual Return Estimates Vs S&P 500
Our best estimate is that Camber Capital Management LP made a return of 0.05% in the last quarter. In trailing 12 months, it's portfolio return was -7.14%.
New Buys
| Ticker | $ Bought |
|---|---|
| qiagen nv | 56,210,000 |
New stocks bought by Camber Capital Management LP
Additions
| Ticker | % Inc. |
|---|---|
| zimmer biomet holdings inc | 40.19 |
| the cigna group | 33.33 |
| baxter intl inc | 24.32 |
| ionis pharmaceuticals inc | 16.00 |
| humana inc | 11.54 |
| biomarin pharmaceutical inc | 11.11 |
| globus med inc | 2.04 |
Additions to existing portfolio by Camber Capital Management LP
Reductions
| Ticker | % Reduced |
|---|---|
| orasure technologies inc | -78.82 |
| ascendis pharma a/s | -56.25 |
| brookdale sr living inc | -55.15 |
| concentra group holdings par | -54.29 |
| ptc therapeutics inc | -53.12 |
| inogen inc | -51.25 |
| viatris inc | -50.00 |
| pfizer inc | -50.00 |
Camber Capital Management LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| herbalife ltd | -20,070,000 |
| medtronic plc | -219,670,000 |
| qiagen nv | -66,795,000 |
| alkermes plc | -43,140,000 |
| jazz pharmaceuticals plc | -141,623,000 |
| merus n v | -10,513,000 |
| brookdale sr living inc | -17,248,000 |
| medpace hldgs inc | -41,529,000 |
Camber Capital Management LP got rid off the above stocks
Sector Distribution
Camber Capital Management LP has about 90.5% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 90.5 |
| Others | 9.5 |
Market Cap. Distribution
Camber Capital Management LP has about 67.2% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| LARGE-CAP | 67.2 |
| MID-CAP | 17.6 |
| UNALLOCATED | 9.5 |
| SMALL-CAP | 5.3 |
Stocks belong to which Index?
About 76.5% of the stocks held by Camber Capital Management LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| S&P 500 | 61.8 |
| Others | 23.5 |
| RUSSELL 2000 | 14.7 |
Camber Capital Management LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Camber Capital Management LP
Camber Capital Management LP has 28 stocks in it's portfolio. About 43.1% of the portfolio is in top 10 stocks. SRPT proved to be the most loss making stock for the portfolio. CVS was the most profitable stock for Camber Capital Management LP last quarter.
Last Reported on: 15 May, 2025| Ticker | Namesorted descending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ZBH | zimmer biomet holdings inc | 9.05 | 2,250,000 | 254,655,000 | added | 40.19 | ||
| BAX | baxter intl inc | 6.99 | 5,750,000 | 196,822,000 | added | 24.32 | ||
| HUM | humana inc | 6.82 | 725,000 | 191,835,000 | added | 11.54 | ||
| CVS | cvs health corp | 5.42 | 2,250,000 | 152,438,000 | reduced | -25.00 | ||
| GMED | globus med inc | 3.25 | 1,250,000 | 91,500,000 | added | 2.04 | ||
| PTCT | ptc therapeutics inc | 2.71 | 1,500,000 | 76,440,000 | reduced | -53.12 | ||
| CI | the cigna group | 2.34 | 200,000 | 65,800,000 | added | 33.33 | ||
| VTRS | viatris inc | 2.32 | 7,500,000 | 65,325,000 | reduced | -50.00 | ||
| PFE | pfizer inc | 2.25 | 2,500,000 | 63,350,000 | reduced | -50.00 | ||
| qiagen nv | 2.00 | 1,400,000 | 56,210,000 | new | ||||
| ascendis pharma a/s | 1.94 | 350,000 | 54,551,000 | reduced | -56.25 | |||
| SRPT | sarepta therapeutics inc | 1.81 | 800,000 | 51,056,000 | reduced | -20.00 | ||
| BKD | brookdale sr living inc | 1.39 | 6,250,000 | 39,125,000 | reduced | -55.15 | ||
| BMRN | biomarin pharmaceutical inc | 1.26 | 500,000 | 35,345,000 | added | 11.11 | ||
| concentra group holdings par | 1.23 | 1,600,000 | 34,720,000 | reduced | -54.29 | |||
| EVH | evolent health inc | 1.01 | 3,000,000 | 28,410,000 | reduced | -25.00 | ||
| IONS | ionis pharmaceuticals inc | 0.78 | 725,000 | 21,873,200 | added | 16.00 | ||
| MYGN | myriad genetics inc | 0.74 | 2,350,000 | 20,844,500 | reduced | -24.19 | ||
| ZIMV | zimvie inc | 0.72 | 1,885,000 | 20,358,000 | reduced | -30.83 | ||
| MLTX | moonlake immunotherapeutics | 0.61 | 441,000 | 17,229,900 | unchanged | 0.00 | ||
